FIA
ENTX icon

FNY Investment Advisers’s Entera Bio ENTX Stock Holding History

FNY Investment Advisers’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-15,189
Closed -$46K – 762
2018
Q4 		$46K Buy
+15,189
New +$75.6K 0.02% 245

Other funds holding ENTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

FNY Investment Advisers's ENTX Position: Q1 2019 in Review

FNY Investment Advisers sold out of Entera Bio (ENTX) in Q1 2019, closing a stake of 15,189 shares — an estimated $46K sold.

FNY Investment Advisers first reported a position in ENTX in Q4 2018 and held it in 1 quarter. The position peaked at $46K in Q4 2018. 7 funds tracked by Wall St. Rank hold ENTX as of Q1 2019.

  • FNY Investment Advisers reported no remaining Entera Bio position as of Q1 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 15,189 Entera Bio shares in Q1 2019, an estimated $46K.
  • FNY Investment Advisers first reported a position in Entera Bio in Q4 2018 and held it in 1 quarter.
  • FNY Investment Advisers's Entera Bio position peaked at $46K in Q4 2018.
  • 7 funds tracked by Wall St. Rank held Entera Bio as of Q1 2019.

Based on FNY Investment Advisers's 13F filing for Q1 2019, filed 17 Apr 2019.